Use of pramipexole in REM sleep behavior disorder: Results from a case series
ABSTRACT Rapid eye movement (REM) sleep behavior disorder (RBD) has a known association with other medical conditions, including narcolepsy and neurodegenerative diseases such as synuclienopathies. RBD is currently treated with clonazepam as a first-line therapy. Recent research suggests that the pathophysiology underlying RBD may involve a dopaminergic deficiency, given its association with Parkinson syndromes and restless legs syndrome (RLS). We report on the efficacy of pramipexole, a dopaminergic D2-3 receptor agonist, in the treatment of RBD.
The first 10 consecutive patients presenting with a history and polysomnographically confirmed RBD were given pramipexole as either a single dose before bedtime or as a divided dose regimen with the first dose given in the early evening and the second dose at bedtime. Medication was titrated to control RBD symptoms and the clinical response was monitored through interviews with the patient, spouse, and close family members during the course of the study at regularly scheduled follow-up visits.
The mean length of treatment was 13.1 months, and the average total evening dose of pramipexole at the end of the study was 0.89+/-0.31 mg. A divided dose regimen of pramipexole was used in 56% of patients remaining on pramipexole. We found that 89% of patients experienced either a moderate reduction or complete resolution in the frequency of RBD symptoms throughout the duration of the study. Moreover, 67% reported at least a moderate reduction in the severity of remaining symptoms.
Pramipexole markedly reduced the frequency and severity of RBD symptoms and appeared to maintain efficacy for up to 25 months as assessed at follow-up visits. Clonazepam may have numerous unwanted side effects in the elderly or narcoleptics with RBD, such as prominent sedation and the potential exacerbation of underlying obstructive breathing in sleep. The potential role of pramipexole in improving RBD and its associated dopamine deficient syndromes warrants further research in the use of dopaminergic agonists as a potential first-line alternative therapy for RBD.
- SourceAvailable from: Radu Constantinescu
[Show abstract] [Hide abstract]
- "(Fantini et al 2003. Schmidt et al 2006) Relja and Klepac, 2006) "
ABSTRACT: Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson's disease (PD). This review addresses the literature concerning pramipexole's efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances.Neuropsychiatric Disease and Treatment 05/2008; 4(2):337-52. DOI:10.2147/NDT.S2325 · 2.15 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: REM behavior disorder (RBD) is a parasomnia characterized by emergence of purposeful complex motor activity with an enactment of dream related activities. This condition is associated with vivid often violent dreams. In normal adults during REM, diffuse hypotonia of muscles occur and on polysomnography the limb and chin electromyographic (EMG) channels demonstrate a low voltage or even flat signal. In RBD, the EMG demonstrating intermittent loss of electromyographic atoniais one of the criteria for diagnosis. Diagnostic polysomnographyrequire capturing the complex dream behaviors on video and electroencephalography monitoring confirms that the behavior originated out of REM sleep. RBD can be either idiopathic or symptomatic of various underlying conditions and may in fact be a prodromal symptom of neurodegenerative disease. It can present acutely which is almost always induced by medications; or develop gradually over months to years. More than half of those with RBD will eventually exhibit signs and symptoms of a degenerative neurologic disorder. A Polysomnogram (PSG) is necessary to diagnose RBD, showing absence of REM sleep atonia and related abnormal behavior.